Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma

被引：0
|
作者：
Chari, Ajai [1 ]
Dimopoulos, Meletios-Athanasios [2 ]
Beksac, Meral [3 ]
Leleu, Xavier [4 ,5 ]
Weisel, Katja [6 ]
Richter, Joshua [7 ]
Dirnberger, Franziska [8 ]
Iskander, Karim [8 ]
Yusuf, Akeem [8 ]
Mikhael, Joseph [9 ]
机构：
[1] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA
[2] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Sch Med, Alexandra Gen Hosp, Athens, Greece
[3] Ankara Univ, Ankara, Turkey
[4] CHU, Serv Hematol & Therapie Cellulaire, Poitiers, France
[5] CIC Inserm 1402, Poitiers, France
[6] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany
[7] Mt Sinai Hosp, Icahn Sch Med, New York, NY 10029 USA
[8] Amgen Inc, Thousand Oaks, CA 91320 USA
[9] City Hope Canc Ctr, Translat Genom Res Inst TGen, Duarte, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-191
引用
收藏
页码：S142 / S142
页数：1
相关论文
共 50 条
  • [31] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Richardson, Paul G.
    Facon, Thierry
    Bensinger, William I.
    Leleu, Xavier
    Campana, Frank
    Mace, Sandrine
    Chiron, Marielle
    van de Velde, Helgi
    Mikhael, Joseph
    BLOOD CANCER JOURNAL, 2021, 11 (03)
  • [32] Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.
    Weisel, Katja C.
    Miguel, Jesus San
    Cook, Gordon
    Leiba, Merav
    Suzuki, Kenshi
    Kumar, Shaji
    Cavo, Michele
    Avet-Loiseau, Herve
    Quach, Hang
    Hungria, Vania
    Lentzsch, Suzanne
    Hajek, Roman
    Sonneveld, Pieter
    Wu, Kaida
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Paul G. Richardson
    Thierry Facon
    William I. Bensinger
    Xavier Leleu
    Frank Campana
    Sandrine Macé
    Marielle Chiron
    Helgi van de Velde
    Joseph Mikhael
    Blood Cancer Journal, 11
  • [34] Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
    Dosne, Anne-Gaelle
    Li, Xia
    Luo, Man Melody
    Nnane, Ivo
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Sonneveld, Pieter
    Kampfenkel, Tobias
    Carson, Robin
    Amin, Himal
    Ruixo, Juan Perez
    Zhou, Honghui
    Sun, Yu-Nien
    Xu, Yan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (05) : 1640 - 1655
  • [35] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study
    Dimopoulos, Meletios A.
    Quach, Hang
    Mateos, Maria-Victoria
    Landgren, Ola
    Leleu, Xavier
    Siegel, David S.
    Weisel, Katja
    Gavriatopoulou, Maria
    Oriol, Albert
    Rabin, Neil K.
    Nooka, Ajay
    Qi, Ming
    Ding, Bifeng
    Zahlten-Kumeli, Anita
    Usmani, Saad Z.
    BLOOD, 2020, 136
  • [36] Weekly Carfilzomib Combined with Daratumumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
    Xu, Jiadai
    Liu, Peng
    BLOOD, 2024, 144 : 7052 - 7053
  • [37] Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
    Trudel, Suzanne
    Beksac, Meral
    Pour, Ludek
    Delimpasi, Sosana
    Quach, Hang
    Vorobyev, Vladimir I.
    Cavo, Michele
    Suzuki, Kazuhito
    Robak, Pawel
    Morris, Kristin
    Phillips-Jones, Amy
    Zhou, Xiaoou Linnette
    Fulci, Giulia
    Sule, Neal
    Kremer, Brandon
    Opalinska, Joanna
    Mateos, Maria-Victoria
    Dimopoulos, Meletios Athanasios
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA105 - LBA105
  • [38] Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma
    Trudel, Suzanne
    Beksac, Meral
    Pour, Ludek
    Delimpasi, Sosana
    Vorobyev, Vladimir
    Hang Quach
    Spicka, Ivan
    Radocha, Jakub
    Robak, Pawel
    Kim, Kihyun
    Cavo, Michele
    Suzuki, Kazuhito
    Morris, Kristin
    Pompilus, Farrah
    Wilkes, Jodie
    Philips-Jones, Amy
    Zhou, Xiaoou
    Fulci, Giulia
    Sule, Neal
    Kremer, Brandon
    Opalinska, Joanna
    Mateos Manteca, Maria-Victoria
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S39 - S40
  • [39] Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Yong, Kwee
    Mikhael, Joseph
    Risse, Marie-Laure
    Asset, Gaelle
    Martin, Thomas
    FUTURE ONCOLOGY, 2020, 16 (02) : 4347 - 4358
  • [40] A SINGLE CENTER EXPERIENCE OF POMALIDOMIDE PLUS DEXAMETHASONE (PD) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
    Duran, M.
    Tombuloglu, M.
    Tobu, M.
    Vural, F.
    Sahin, F.
    Patir, P.
    Uysal, A.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S18 - S19
12345